Gossamer Bio, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Faheem Hasnain
- Full Time Employees
- 162
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3115 Merryfield Row San Diego CA United States of America 92121
- IPO Date
- Feb 8, 2019
- CIK
- 0001728117
- Website
- gossamerbio.com
- Similar Companies
- Business
- Gossamer Bio, Inc. is a clinical-stage biopharmaceutical entity engaged in the advancement of novel therapeutic agents for significant unmet medical needs, operating from its headquarters in San Diego, California. The company's primary focus centers on seralutinib (GB002), an inhaled, small molecule designed to address pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib functions as an inhibitor of platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, aiming to target the underlying vascular remodeling, inflammation, and fibrosis characteristic of these conditions. Presently, seralutinib is undergoing a global registrational Phase 3 clinical trial, known as the PROSERA Study, for the treatment of PAH, with patient screening recently concluded and topline results anticipated in the fourth quarter of 2025 or early 2026. Furthermore, the company is preparing to initiate the Phase 3 SERANATA Study for PH-ILD, with site activations planned for the fourth quarter of 2025. Gossamer Bio has forged a strategic collaboration with the Chiesi Group for the development and commercialization of seralutinib. The company also holds a licensing arrangement with Pulmokine, Inc. for seralutinib and related backup compounds. Expanding its pipeline in this therapeutic area, Gossamer Bio recently secured an option to acquire Respira Therapeutics and its lead candidate, RT234, an inhaled, on-demand vardenafil also intended for pulmonary hypertension. The firm's overarching objective is to be a leader in improving the lives of individuals affected by pulmonary hypertension. Gossamer Bio, Inc. was established in 2015.
Company News
Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate
Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm